Compare Novo Nordisk A/S (NVO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs PAGSEG Inc — how do they compare? Novo Nordisk A/S trades at $46.28 (market cap $207.85B), while PAGSEG Inc trades at $8.97 (market cap $2.48B). The key difference: Novo Nordisk A/S is far larger — about 83.8× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.7%). Which is the better fit depends on your goals.
| NVO | PAGS | |
|---|---|---|
Market Cap | $207.85B | $2.48B |
Sector | Health | Technology |
52-Week High | $63.98 | $12.00 |
52-Week Low | $35.29 | $8.38 |
Enterprise Value | $222.55B | $10.22B |
Dividend Yield | 3.81% | 11.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.465, down 2.65% today, with a neutral technical signal. The stock shows strong fundamentals, including a P/E of 11.62, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights competitive pressures from Eli Lilly and mixed investor reactions to Q2 2026 results, despite an upwardly revised full-year outlook.
Outlook remains positive due to robust GLP-1 drug demand and profitability, but risks include pricing pressure and competition. Analysts are predominantly bullish (57.9% buy ratings), supporting a favorable long-term view despite near-term volatility.
PAGS trades at $8.70, down 4.19% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a P/E of 6.17 and net income margin of 10.4%, while Q2 2026 earnings beat expectations. Recent news highlights robust Q2 2026 results, including R$576 million recurring net income and growth in deposits and loans, per PRNewsWire on August 12, 2026.
The outlook is mixed; low valuations and analyst consensus of $11.45 price target suggest upside, but technical bearishness and CEO share sales pose risks. Investors may find value in earnings growth potential, though market volatility and competitive pressures require caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
